Endo, Impax Schemed To Delay Opana Generics, Suit Says
Endo Pharmaceuticals Inc. and Impax Laboratories Inc. were hit with a proposed antitrust class action in Pennsylvania federal court Wednesday alleging Endo paid Impax more than $112 million to delay generic...To view the full article, register now.
Already a subscriber? Click here to view full article